|

A Study of BGM-2121 in Patients With Advanced Solid Tumors

RECRUITINGPhase 1Sponsored by BioGate Precision Medicine Corp.
Actively Recruiting
PhasePhase 1
SponsorBioGate Precision Medicine Corp.
Started2026-03-10
Est. completion2027-11
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07346846

Summary

This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. With either gender aged ≥ 18 years,
2. Has a confirmed diagnosis of advanced solid tumor(s),
3. The subject has received and failed standard-of-care anti-cancer therapy
4. Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)
5. ...

Exclusion Criteria:

1. Has any ongoing toxicity from previous anti-cancer treatments
2. Has signs or symptoms of end-stage organ failure, major chronic illnesses other than cancer(s)
3. History of another primary malignancy within the last three years
4. ...

Conditions2

Advanced Solid TumorsCancer

Interventions1

BGM-2121

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.